ATE330622T1 - Mit aminosäuren stabilisierte erythropoietinlösung - Google Patents
Mit aminosäuren stabilisierte erythropoietinlösungInfo
- Publication number
- ATE330622T1 ATE330622T1 AT97919693T AT97919693T ATE330622T1 AT E330622 T1 ATE330622 T1 AT E330622T1 AT 97919693 T AT97919693 T AT 97919693T AT 97919693 T AT97919693 T AT 97919693T AT E330622 T1 ATE330622 T1 AT E330622T1
- Authority
- AT
- Austria
- Prior art keywords
- amino acids
- erythropoietin solution
- solution stabilized
- erythropoietin
- stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13122696 | 1996-04-26 | ||
JP30395696 | 1996-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE330622T1 true ATE330622T1 (de) | 2006-07-15 |
Family
ID=26466124
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06012448T ATE477813T1 (de) | 1996-04-26 | 1997-04-25 | Erythropoietin-lösungszubereitung, stabilisiert mit leucin oder glutaminsäure |
AT97919693T ATE330622T1 (de) | 1996-04-26 | 1997-04-25 | Mit aminosäuren stabilisierte erythropoietinlösung |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06012448T ATE477813T1 (de) | 1996-04-26 | 1997-04-25 | Erythropoietin-lösungszubereitung, stabilisiert mit leucin oder glutaminsäure |
Country Status (10)
Country | Link |
---|---|
US (4) | US6120761A (de) |
EP (2) | EP1712237B1 (de) |
JP (3) | JP3068033B2 (de) |
KR (2) | KR100417031B1 (de) |
AT (2) | ATE477813T1 (de) |
AU (1) | AU722300B2 (de) |
DE (2) | DE69739968D1 (de) |
ES (1) | ES2267140T3 (de) |
TW (2) | TWI240627B (de) |
WO (1) | WO1997040850A1 (de) |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI240627B (en) * | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
JP2011025068A (ja) * | 1999-02-22 | 2011-02-10 | Chugai Pharmaceut Co Ltd | プレフィルドシリンジタンパク質溶液製剤 |
JP2007204498A (ja) * | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
NZ515380A (en) * | 1999-04-09 | 2003-10-31 | Ortho Mcneil Pharm Inc | Aqueous stable preserved pharmaceutical compositions of erythropoietin |
JP5271481B2 (ja) * | 1999-09-08 | 2013-08-21 | 中外製薬株式会社 | タンパク質溶液製剤およびその安定化方法 |
EP1232753B1 (de) * | 1999-09-08 | 2008-03-19 | Chugai Seiyaku Kabushiki Kaisha | Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben |
GB9930882D0 (en) * | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
AU2001236005A1 (en) * | 2000-02-29 | 2001-09-12 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilized over long time |
AU2005225151B2 (en) * | 2000-05-15 | 2008-05-29 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
ES2237574T5 (es) * | 2000-05-15 | 2017-08-09 | F. Hoffmann-La Roche Ag | Composición farmacéutica líquida que contiene un derivado de eritropoyetina |
JP5490972B2 (ja) * | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
JP4147234B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、カートリッジ及び吐出装置 |
SI1324776T2 (en) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Concentrated protein formulations with reduced viscosity |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
AU2002233230B2 (en) | 2000-12-20 | 2007-02-01 | F. Hoffmann-La Roche Ag | Erythropoietin conjugates |
EP2975382B1 (de) * | 2001-04-17 | 2017-12-27 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur quantifizierung eines grenzflächenaktiven mittels |
US7682608B2 (en) | 2001-08-29 | 2010-03-23 | Chugai Seiyaku Kabushiki Kaisha | Stabilized preparations containing antibody |
EP1450847B1 (de) * | 2001-11-13 | 2010-09-29 | Genentech, Inc. | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
US7842668B1 (en) | 2001-11-13 | 2010-11-30 | Genentech, Inc. | Apo-2 ligand/trail formulations |
US7741285B2 (en) * | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
CA2470511C (en) | 2001-12-21 | 2014-05-27 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
ES2311094T3 (es) | 2002-02-27 | 2009-02-01 | Immunex Corporation | Composicion estabilizada de tnfr-fc que comprende arginina. |
ES2523655T5 (es) | 2002-06-21 | 2018-04-23 | Novo Nordisk Health Care Ag | Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa |
WO2004007520A2 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
SI21257A (sl) * | 2002-07-17 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Stabilni farmacevtski pripravek, ki vsebuje eritropoietin |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
ZA200507486B (en) | 2003-03-07 | 2007-03-28 | Astellas Pharma Inc | Nitrogenous heterocyclic derivative having 2,6-disubstituted styryl |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
US20040198663A1 (en) * | 2003-04-04 | 2004-10-07 | Baker John E. | Method of treating cardiac ischemia by using erythropoietin |
WO2004103398A1 (en) | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
JP4871720B2 (ja) * | 2003-06-10 | 2012-02-08 | エルジー ライフサイエンス リミテッド | 血清アルブミンを含まない、安定なヒトエリスロポエチン水溶液 |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
KR100560697B1 (ko) * | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | 알부민을 함유하지 않는 에리스로포이에틴 제제 |
MXPA06001698A (es) * | 2003-08-14 | 2006-05-19 | Novo Nordisk Healthcare Ag | Composicion farmaceutica liquida y acuosa de polipetidos de factor vii. |
US7141544B2 (en) * | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
EP1537876A1 (de) * | 2003-12-01 | 2005-06-08 | BioGeneriX AG | Formulierung einer Erythropoietin Lösung |
EP3378470A1 (de) | 2003-12-19 | 2018-09-26 | Novo Nordisk Health Care AG | Stabilisierte zusammensetzungen aus faktor-vii-polypeptiden |
DE102004011663B4 (de) * | 2004-03-10 | 2006-04-27 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
US20050282751A1 (en) * | 2004-03-19 | 2005-12-22 | Ajinomoto Co., Inc. | Therapeutic agent for renal anemia |
SG151298A1 (en) * | 2004-04-08 | 2009-04-30 | Biomatrica Inc | Integration of sample storage and sample management for life science |
US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
CA2565414A1 (en) | 2004-05-04 | 2005-11-24 | Novo Nordisk Health Care Ag | O-linked glycoforms of polypeptides and method to manufacture them |
US20060029551A1 (en) * | 2004-08-05 | 2006-02-09 | Kui Liu | Stable particle formulations of erythropoietin receptor agonists |
US7772182B2 (en) | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
JP4147235B2 (ja) * | 2004-09-27 | 2008-09-10 | キヤノン株式会社 | 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置 |
JP2008515955A (ja) * | 2004-10-12 | 2008-05-15 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 貧血の治療のためのPI3キナーゼγ阻害剤 |
MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
EP1884235A1 (de) * | 2005-04-26 | 2008-02-06 | Ajinomoto Co., Inc. | Die differenzierung myeloerythroider progenitorzellen induzierende substanz |
KR20080031684A (ko) | 2005-06-14 | 2008-04-10 | 암젠 인코포레이티드 | 자가 - 완충성 단백질 제형 |
JP5033798B2 (ja) * | 2005-07-02 | 2012-09-26 | アレコー・リミテッド | タンパク質を含む安定水系 |
GB2433425B (en) * | 2005-12-23 | 2010-11-17 | Cassidy Brothers Plc | Improvements relating to vacuum cleaners |
JP5553506B2 (ja) * | 2006-03-22 | 2014-07-16 | 中外製薬株式会社 | エリスロポエチン溶液製剤 |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
RU2008152746A (ru) | 2006-06-07 | 2010-07-20 | Дзе Юниверсити Оф Токусима (Jp) | Лечение ишемических заболеваний с применением эритропоэтина |
CA2659990C (en) | 2006-08-04 | 2016-03-22 | Prolong Pharmaceuticals, Inc. | Polyethylene glycol erythropoietin conjugates |
WO2008023725A1 (fr) | 2006-08-22 | 2008-02-28 | Chugai Seiyaku Kabushiki Kaisha | Agent préventif et/ou thérapeutique pour une neuropathie périphérique |
KR100784134B1 (ko) | 2006-10-09 | 2007-12-12 | 주식회사 대웅 | 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물 |
WO2008086025A2 (en) * | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
AR065613A1 (es) | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
US20080268514A1 (en) * | 2007-04-24 | 2008-10-30 | Rolf Muller | Sample storage for life science |
CL2008002053A1 (es) * | 2007-07-17 | 2009-05-22 | Hoffmann La Roche | Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion. |
AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
CN102066401A (zh) | 2008-05-01 | 2011-05-18 | 艾瑞克有限公司 | 蛋白质制品 |
US20090291092A1 (en) * | 2008-05-22 | 2009-11-26 | Miller Guy M | Treatment of mitochondrial diseases with an erythropoietin mimetic |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
US8519125B2 (en) * | 2009-05-11 | 2013-08-27 | Biomatrica, Inc. | Compositions and methods for biological sample storage |
KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
RU2012135505A (ru) * | 2010-01-19 | 2014-02-27 | Ханми Сайенс Ко., Лтд. | Жидкие составы для конъюгата этитропоэтина длительного действия |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
BR112012022258A2 (pt) | 2010-03-01 | 2016-10-25 | Bayer Healthcare Llc | anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi) |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
JP5933544B2 (ja) | 2010-07-26 | 2016-06-08 | バイオマトリカ, インコーポレーテッド | 外界温度で出荷および貯蔵中の血中dna、rnaおよびタンパク質ならびに他の生体試料を安定化させるための組成物 |
WO2012018639A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
JP5887893B2 (ja) * | 2010-12-10 | 2016-03-16 | 大正製薬株式会社 | 内服液剤 |
CN104080441B (zh) | 2011-11-30 | 2020-02-28 | 3M创新有限公司 | 包括肽治疗剂和氨基酸的微针装置、制备和使用其的方法 |
EP2849755A1 (de) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | Xanthinderivat als dpp-4-hemmer zur verwendung bei der behandlung von durch podozyten vermittelten erkrankungen und/oder des nephrotischen syndroms |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
EP2934572A4 (de) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | Formulierungen und verfahren zur stabilisierung von pcr-reagenzien |
EP3125922B1 (de) | 2014-03-29 | 2020-10-14 | Intas Pharmaceuticals Limited | Flüssige pharmazeutische zusammensetzung von konjugiertem erythropoietin |
EP3656215B1 (de) | 2014-06-10 | 2021-08-04 | Biomatrica, INC. | Stabilisierung von thrombozyten bei umgebungstemperatur |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
IL255148B2 (en) | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
HUE052634T2 (hu) | 2015-11-23 | 2021-05-28 | Bristol Myers Squibb Co | Adalékrendszerek felhasználásra protein pegilálásban |
AU2016368265B2 (en) | 2015-12-08 | 2021-10-28 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
SI3463432T1 (sl) * | 2016-05-27 | 2021-02-26 | Ipsen Biopharm Limited | Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom |
WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
BR112019007858A2 (pt) | 2016-10-21 | 2019-07-02 | Amgen Inc | formulações farmacêuticas e métodos para produzir as mesmas |
KR102322802B1 (ko) | 2017-01-05 | 2021-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
US11110063B2 (en) | 2017-08-25 | 2021-09-07 | MAIA Pharmaceuticals, Inc. | Storage stable sincalide formulations |
IL279853B1 (en) | 2018-07-04 | 2024-09-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
JPH0669960B2 (ja) * | 1985-11-22 | 1994-09-07 | エーザイ株式会社 | 水溶性を増加したtPA含有医薬組成物 |
JP2577744B2 (ja) * | 1986-07-18 | 1997-02-05 | 中外製薬株式会社 | 安定な顆粒球コロニ−刺激因子含有製剤 |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
JP2708749B2 (ja) * | 1987-08-10 | 1998-02-04 | エーザイ株式会社 | 修飾型tPA含有注射用組成物 |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
JP2844351B2 (ja) * | 1989-07-13 | 1999-01-06 | 株式会社科薬 | 安定なポリミキシン系抗生物質水性溶液 |
DE3939346A1 (de) * | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
JPH078804B2 (ja) * | 1990-08-28 | 1995-02-01 | 三菱化学株式会社 | 副腎皮質刺激ホルモン放出因子含有製剤 |
DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
JP3221120B2 (ja) * | 1992-12-25 | 2001-10-22 | ソニー株式会社 | 復号装置 |
US6288030B1 (en) * | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
JP3044333B2 (ja) | 1994-06-10 | 2000-05-22 | 大日本スクリーン製造株式会社 | 減圧式基板処理槽の蓋開閉装置 |
US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
GB9424902D0 (en) * | 1994-12-09 | 1995-02-08 | Cortecs Ltd | Solubilisation Aids |
ATE201983T1 (de) * | 1995-03-10 | 2001-06-15 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
JP3170437B2 (ja) | 1995-09-20 | 2001-05-28 | 株式会社日立製作所 | 不揮発性半導体多値記憶装置 |
TWI240627B (en) * | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
-
1997
- 1997-04-24 TW TW091133042A patent/TWI240627B/zh not_active IP Right Cessation
- 1997-04-24 TW TW086105353A patent/TW518219B/zh not_active IP Right Cessation
- 1997-04-25 KR KR10-1998-0708509A patent/KR100417031B1/ko not_active IP Right Cessation
- 1997-04-25 AT AT06012448T patent/ATE477813T1/de active
- 1997-04-25 AU AU24074/97A patent/AU722300B2/en not_active Expired
- 1997-04-25 AT AT97919693T patent/ATE330622T1/de not_active IP Right Cessation
- 1997-04-25 ES ES97919693T patent/ES2267140T3/es not_active Expired - Lifetime
- 1997-04-25 WO PCT/JP1997/001449 patent/WO1997040850A1/ja active IP Right Grant
- 1997-04-25 KR KR10-2003-7005786A patent/KR20040004414A/ko not_active Application Discontinuation
- 1997-04-25 EP EP06012448A patent/EP1712237B1/de not_active Expired - Lifetime
- 1997-04-25 US US09/171,737 patent/US6120761A/en not_active Expired - Lifetime
- 1997-04-25 DE DE69739968T patent/DE69739968D1/de not_active Expired - Lifetime
- 1997-04-25 EP EP97919693A patent/EP0909564B1/de not_active Expired - Lifetime
- 1997-04-25 DE DE69736177T patent/DE69736177T2/de not_active Expired - Lifetime
- 1997-04-25 JP JP9123169A patent/JP3068033B2/ja not_active Expired - Lifetime
-
1999
- 1999-12-21 US US09/468,772 patent/US6277367B1/en not_active Expired - Lifetime
-
2000
- 2000-03-31 JP JP2000097633A patent/JP3618633B2/ja not_active Expired - Lifetime
-
2001
- 2001-07-18 US US09/909,429 patent/US6627187B2/en not_active Expired - Lifetime
-
2003
- 2003-09-29 US US10/674,446 patent/US7011825B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 JP JP2004072830A patent/JP4589018B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1712237B1 (de) | 2010-08-18 |
DE69739968D1 (de) | 2010-09-30 |
TW200300340A (en) | 2003-06-01 |
TWI240627B (en) | 2005-10-01 |
AU722300B2 (en) | 2000-07-27 |
TW518219B (en) | 2003-01-21 |
KR100417031B1 (ko) | 2004-07-19 |
DE69736177D1 (de) | 2006-08-03 |
EP1712237A3 (de) | 2008-05-07 |
JP4589018B2 (ja) | 2010-12-01 |
WO1997040850A1 (fr) | 1997-11-06 |
DE69736177T2 (de) | 2007-05-16 |
US20010055582A1 (en) | 2001-12-27 |
US20040087507A1 (en) | 2004-05-06 |
US7011825B2 (en) | 2006-03-14 |
EP0909564A4 (de) | 2003-03-26 |
KR20040004414A (ko) | 2004-01-13 |
JP2004196824A (ja) | 2004-07-15 |
US6277367B1 (en) | 2001-08-21 |
JP3068033B2 (ja) | 2000-07-24 |
EP0909564A1 (de) | 1999-04-21 |
EP1712237A2 (de) | 2006-10-18 |
ES2267140T3 (es) | 2007-03-01 |
US6627187B2 (en) | 2003-09-30 |
JP3618633B2 (ja) | 2005-02-09 |
US6120761A (en) | 2000-09-19 |
ATE477813T1 (de) | 2010-09-15 |
AU2407497A (en) | 1997-11-19 |
JPH10182481A (ja) | 1998-07-07 |
KR20000064995A (ko) | 2000-11-06 |
EP0909564B1 (de) | 2006-06-21 |
JP2000302689A (ja) | 2000-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE330622T1 (de) | Mit aminosäuren stabilisierte erythropoietinlösung | |
DE68907707D1 (de) | Enzymstabilisierung. | |
DE69404118D1 (de) | Stromgesteuerter, spannungsempfindlicher Laserdiodentreiber | |
DK0713529T3 (da) | Vækst-/differentieringsfaktor af TGF-beta-familien | |
DE59008394D1 (de) | Aminosäureamid-Derivate. | |
DK1454138T3 (da) | Immunocytokiner med moduleret selektivitet | |
ATE128816T1 (de) | Mit säure stabilisierte teigwaren. | |
NO954080D0 (no) | Amino(tio)eterderivater | |
DE60139944D1 (de) | Niederviskose konzentrierte proteinformulierungen | |
DE68915207D1 (de) | Aminosäure-Derivate. | |
DE60032367D1 (de) | Aktivierbare rekombinante neurotoxine | |
IL108206A0 (en) | Oligomers having improved stability at acid ph | |
DE69319429D1 (de) | Pvc-zusammensetzung von elektroqualität, stabilisiert mit bleifreien stabilisator | |
EP0629853A3 (de) | Kapillarelektroforese mit gleichlaufenden Trennungsfeldern. | |
FI955130A (fi) | L-aminohappo-oksidaasi | |
PT882726E (pt) | Carbazol-carboxamidas como agonistas 5-ht1f | |
EP1000923A4 (de) | Cyclopentenonderivate | |
ATE250021T1 (de) | Hydroxycyclopentanone | |
EP0661786A3 (de) | Vielfachdiodenlaser mit geringem Strahlabstand. | |
AU7049296A (en) | Stabilization of non-halogenated 3-isothiazolones in aggressive systems | |
DE59301060D1 (de) | Substituierte Aminosäureamide. | |
TR27243A (tr) | Antimikrobiyal proteinler. | |
DE59106215D1 (de) | Substituierte Aminosäureamid-Derivate, deren Herstellung und Verwendung. | |
DE59105160D1 (de) | Substituierte Aminosäureamid-Derivate deren Herstellung und Verwendung. | |
DE69731682D1 (de) | TAB1 Protein und dafür kodierende DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |